IV Dexmedetomidine in the Duration of Spinal Anesthesia With Hyperbaric Bupivacaine: Double Blind Randomized Trial.
Status:
Recruiting
Trial end date:
2022-05-15
Target enrollment:
Participant gender:
Summary
Introduction: Spinal anesthesia produces sensitive and motor block according to the
administered local anesthetic. The total duration of surgical anesthesia depends on the dose,
intrinsic properties of the anesthetic, and the use of additional drugs. Dexmedetomidine is
an alpha-2 adrenergic agonist that has sedative and analgesic effects. The specific action
site in the spinal cord receptors and in the locus coeruleus provide as well hypnotic and
sympatholytic characteristics. The combination of spinal anesthesia and intravenous
dexmedetomidine is a safe option for hemodynamically stable patients undergoing elective
surgery. Material and methods: Double blind randomized trial. The objective is to time and
compare the total duration of neuraxial blockade with spinal hyperbaric bupivacaine plus
intravenous dexmedetomidine, against hyperbaric bupivacaine by itself. 60 patients shall be
included, between the ages of 18 and 65 years, classified by the American Society of
Anesthesiologists (ASA) I and II, undergoing lower limb elective orthopedic procedure, with
spinal anesthesia plus epidural catheter. 50% of the patients (group A) will receive spinal
hyperbaric bupivacaine and IV dexmedetomidine at 0.5 mcg/kg (real weight), and the other 50%
(group B) will receive spinal hyperbaric bupivacaine plus IV 0.9% saline solution in
equivalent volume.